Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 4, 2002, Pages 445-464

  Behr, Thomas M ^a,b   Beéheé, Martin ^a,b   Sgouros, George ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alpha emitters; Auger conversion electron emitters; Beta emitters; Dose rate; IgG; Linear energy transfer (LET); Monoclonal antibody; Myelotoxicity; Radioimmunotherapy; Radiopeptide therapy; Red marrow dosimetry; Relative biological effectiveness (RBE) factor

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; IODINE 125; IODINE 131; PEPTIDE; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUGER ELECTRON SPECTROSCOPY; BONE MARROW; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG MIXTURE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; METASTASIS; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGIC EFFECTIVENESS; RISK FACTOR; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LINEAR ENERGY TRANSFER; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE;

EID: 0036380543     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760363231     Document Type: Article

References (68)

1. 131I-labeled antiCEA murine IgG monoclonal antibody. J. Nucl. Med. 1997; 38: 858-870.
2. Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Badger, C.C., Nelp, W.B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D.C., Fisher, L.D., and Bernstein, I.D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 1993; 329: 1219-1224.
3. Blumenthal, R.D., Sharkey, R.M., Forman, D., Wong, G., Hess, J., and Goldenberg, D.M. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol., 1995; 23: 1088-1097.
4. Harbert, J.C., Eckelman, W.C., and Neumann, R.D. (eds.). Nuclear Medicine: Diagnosis and Therapy. Thieme Medical Publishers, New York 1996.
5. Sgouros, G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med. 1993; 34: 689-694.
6. Behr, T.M., Holler, E., Gratz, S., Wörmann, B., Sharkey, R.M., Dunn, R.M., Hiddemann, W., Kolb, H.J., Goldenberg, D.M., and Becker, W. CD22 is a suitable target molecule for detection and high-dose, myeloablative radioimmunotherapy with the monclonal antibody LL2 in acute lymphatic leukemia and Waldenström's macroglobulinemia. Tumor Targeting 1998; 3: 32-40.
7. Hendry, J.H., and Lord, B.I. (eds.). Radiation Toxicology-Bone Marrow and Leukaemia. London/Bristol: Taylor & Francis, 1995.
8. th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg (TN) 1996, 1999; Volume 1: 113-126.
9. Muthuswamy, M.S., Roberson, P.L., and Buchsbaum, D.L.: A mouse bone marrow dosimetry model. J. Nucl. Med. 1998; 39: 1243-1247.
10. 2 fragments. J. Nucl. Med. 1991; 32: 1414-1421.
11. 131I-labeled monoclonal antibodies administered to man. Int. J. Rad. Appl. Instrum B. 1989; 16: 153-158.
12. Zanzonico, P., and Sgouros, G. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute? J. Nucl. Med. 1997; 38: 1753-1754.
13. Juweid, M., Sharkey, R.M., Siegel, J.A., Behr, T., and Goldenberg, D.M. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy in patients having Non-Hodgkin's lymphoma (NHL) and diffuse bone marrow uptake. Cancer Res. 1995; 55: 5827s-5831s.
14. Sgouros, G., Jureidini, I.M., Scott, A.M., Graham, M.C., Larson, S.M., and Scheinberg, D.A. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J. Nucl. Med. 1996; 37: 695-698.
15. Siegel, J.A., Lee, R.E., Pawlyk, D.A., Horowitz, J.A., Sharkey, R.M., and Goldenberg, D.M. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int. J. Rad. Appl. Instrum. B. 1989; 16: 553-559.
16. Behr, T.M., Sharkey, R.M., Sgouros, G., Blumenthal, R.D., Dunn, R.M., Kolbert, K., Griffiths, G.L., Siegel, J.A., Becker, W.S., and Goldenberg D.M. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80: 2591-2610.
17. Behr, T.M., Memtsoudis, S., Sharkey, R.M., Blumenthal, R.D., Dunn, R.M., Gratz, S., Wieland, E., Nebendahl, K., Schmidberger, H., Goldenberg, D.M., and Becker, W. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer 1998, 77: 787-795.
18. Hall, E.J. Radiobiology for the Radiologist. Philadelphia: J.B. Lippincott, 1994.
19. Walden Jr., T.L., and Farzaneh, N.K. Biochemistry of Ionizing Radiation. New York: Raven Press, 1990.
20. th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg (TN) 1996, 1999; Volume 1: 257-271.
21. Behr, T.M., Sgouros, G., Sharkey, R.M., Dunn, R.M., Blumenthal, R.D., Kolbert, K., Siegel, J.A., and Goldenberg, D.M. Y-90-dosimetry in nude mice requires accounting for cross-organ radiation: evaluation of three dosimetry models in relation to observed biological effects. J. Nucl. Med. 1996; 37: 102P.
22. Behr, T.M., Sgouros, G., Stabin, M.G., Béhé, M., Angerstein, C., Blumenthal, R.D., Apostolidis, C., Molinet, R., Sharkey, R.M., Koch, L., Goldenberg, D.M., and Becker W. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin. Cancer Res. 1999, 5: 3031-3043.
23. 131I-labeled CO17-1A in a human colorectal cancer model. Int. J. Cancer 1998; 76: 738-748.
24. Hansen, H.J., Goldenberg, D.M., Newman, E.S., Grebenau, R., and Sharkey, R.M. Characterization of secondgeneration monoclonal antibodies against carcinoembryonic antigen. Cancer 1993; 71: 3478-3485.
25. Sharkey, R.M., Goldenberg, D.M., Murthy, S., Pinsky, H., Vagg, R., Pawlyk, D., Siegel, J.A., Wong, G.Y., Gascon, P., Izon, D.O., Vezza, M., Burger, K., Swayne, L.C., Pinsky, C.M., and Hansen, H.J. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer, 1993; 71: 2082-2096.
26. Sharkey, R.M., Juweid, M., Shevitz, J., Behr, T., Dunn, R., Swayne, L.C., Wong, G.Y., Blumenthal, R.D., Griffiths, G.L., Siegel, J.A., Leung, S., Hansen, H.J., and Goldenberg, D.M. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995; 55: 5935-5945.
27. Behr, T.M., Wulst, E., Radetzky, S., Blumenthal, R.D., Dunn, R.M., Gratz, S., Rave-Fränk, M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 1997; 57: 5309-5319.
28. Pawlak-Byczkowska, E.J., Hansen, H.J., Dion, A.S., and Goldenberg, D.M. Two new monoclonal antibodies reactive with human lymphoma. Cancer Res. 1989; 49: 4568-4577.
29. Goldenberg, D.M., Horowitz, J.A., Sharkey, R.M., Hall, T.C., Murthy, S., Goldenberg, H., Lee, R.E., Stein, R., Siegel, J.A., Izon, D.O., Burger, K., Swayne, L.C., Belisle, E., Hansen, H.J., and Pinsky, C.M. Targeting, dosimetry and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol. 1991; 9: 548-564.
30. Juweid, M., Sharkey, R.M., Markowitz, A., Behr, T., Swayne, L.C., Hansen, H.J., Shevitz, J., Leung, S., Rubin, A.D., Herskovic, T., Hanley, D., and Goldenberg D.M. Treatment of Non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995; 55: 5899-5907.
31. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D., and Dallaire, B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825-2833.
32. Behr, T.M., Wörmann, B., Gramatzki, M., Riggert, J., Gratz, S., Béhé, M., Griesinger, F., Sharkey, R.M., Kolb, H.J., Hiddemann, W., Goldenberg, D.M., and Becker W. Radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies: low- versus high-dose, myeloablative regimens in acute lymphatic leukemia, high- and low-grade non-Hodgkin's lymphoma, and macroglobulinemia. Clin. Cancer Res. 1999; 5: 3304-3314.
33. Brechbiel, M.W., Gansow, O.A., Achter, R.W., Schlom, J., Esteban, J.M., Simpson, D.E., Colcher, D. Synthesis of 1-(p-isothiocyanobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg. Chem. 1986; 25: 2772-2781.
34. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999; 59: 2635-2643.
35. Furhang, E.E., Sgouros, G., and Chui, C.S. Radionuclide photon dose kernels for internal emitter dosimetry. Med. Phys. 1996; 23: 759-764.
36. Goddu, S.M., Howell, R.W., and Rao, D.V. Generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J. Nucl. Med. 1995; 36: 1923-1927.
37. Goddu, S.M., Howell, R.W., and Rao, D.V. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med. 1994; 35: 303-316.
38. Yoriyaz, H., and Stabin, M. Electron and photon transport in a model of a 30g mouse. J. Nucl. Med. 1997; 38: 228P.
39. Behr, T.M., Memtsoudis, S., Vougioukas, V., Liersch, T., Gratz, S., Schmidt, F., Lorf, T., Post, S., Wörmann, B., Hiddemann, W., Ringe, B., and Becker, W. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial. Anti- cancer Res. 1999; 19: 2427-2432.
40. Behr, T.M., Salib, A.L., Liersch, T., Béhé, M., Angerstein, C., Blumenthal, R.D., Fayyazi, A., Sharkey, R.M., Ringe, B., Becker, H., Wörmann, B., Hiddemann, W., Goldenberg, D.M., and Becker W. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phaseI clinical study. Clin. Cancer Res. 1999; 5: 3232-3242.
41. 131I-labeled humanized anti-CEA antibody, hMN-14. Cancer, 2002: 94: 1373-1381.
42. Behr, T.M., Wörmann, B., Gramatzki, M., Riggert, J., Gratz, S., Béhé, M., Griesinger, F., Sharkey, R.M., Kolb, H.J., Hiddemann, W., Goldenberg, D.M., and Becker, W. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies. Clin. Cancer Res. 1999; 5: 3304-3314.
43. Stabin, M.G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 1996; 37: 538-546.
44. Bowalekar, S.K. Statistics in medical research: IV. Sampling distribution, statistical testing of hypothesis and student's t-test. J. Postgrad. Med. 1994; 40: 46-51.
45. Shadduck, R.K., Waheed, A., and Wing, E.J. Demonstration of a blood-bone marrow barrier to macrophage colony-stimulating factor. Blood 1989; 73: 68-73.
46. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug. Radiopharm. 1990; 3: 213-233.
47. Glasgow, G.P., Beetham, K.L., and Mill, W.B. Dose rate effects on the survival of normal hematopoietic stem cells of BALB/c mice. Int. J. Radiat. Oncol. Biol. Phys. 1983; 9: 557-563.
48. Tarbell, N.J., Amato, D.A., Down, J.D., Mauch, P., and Hellman, S. Fractionation and dose rate effects in mice: a model for bone marrow tranplantation in man. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 1065-1069.
49. FitzGerald, T.J., Santucci, M.A., Harigaya, K., Woda, B., McKenna, M., Sakakeeny, M.A., Pierce, J.H., Kase, K., Holland, C.A., and Greenberger, J.S. Radiosensitivity of permanent human bone marrow stromal cell lines: effects of dose rate. Int. J. Radiat. Oncol. Biol. Phys. 1988; 15: 1153-1159.
50. Down, J.D., Tarbell, N.J., Thames, H.D., and Mauch, P.M. Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation. Blood 1991; 77: 661-669.
51. van Os, R., Thames, H.D., Konings, A.W., and Down, J.D. Radiation dose-fractionation and dose-rate relationships for long-term repopulating hemopoietic stemm cells in a murine bone marrow transplant model. Radiat. Res. 1993; 136: 118-125.
52. Yamamoto, O., Yokoro, K., Seyama, T., Kinomura, A., Nomura, T. HTO oral administration in mice. I. Threshold dose rate for haematopoietic death. Int. J. Radiat. Biol. 1990; 57: 543-549.
53. Howell, R.W., Goddu, S.M., and Rao D.V. Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J. Nucl. Med. 1997; 38: 727-731.
54. Goddu, S.M., Howell, R.W., and Rao, D.V. Biologic dosimetry of bone marrow: implications for radionuclide therapy. Tumor Targeting 1996; 2: 146 (abstract 23).
55. Mackova, N., and Praslicka, M. Recovery of hematopoiesis in bone marrow of mice after continuous irradiation with dose rate 4.8 Gy/day. Neoplasma 1981; 28: 79-86.
56. Abkowitz, J.L., Persik, M.T., Shelton, G.H., Ott, R.L., Kiklevich, J.V., Catlin, S.N., Guttorp, P. Behavior of hematopoietic stem cells in a large animal. Proc. Natl. Acad. Sci. USA 1995; 92 (6): 2031-2035.
57. Jones, T.D., Morris, M.D., Young, R.W. Mathematical models of marrow cell kinetics: differential effects of protracted irradiations on stromal and stem cells in mice. Int. J. Radiat. Oncol. Biol. Phys. 1993; 26 (5): 817-830.
58. Wagner, J.L., Storb, R. Preclinical large animal models for hematopoietic stem cell transplantation. Curr Opin Hematol 1996; 3 (6): 410-415.
59. Howell, R.W., Azure, M.T., Narra, V.R., Rao, D.V. Relative biological effectiveness of alpha-emitters in vivo at low doses. Radiat. Res. 1994; 137: 352-360.
60. Howell, R.W., Goddu, S.M., Narra, V.R., Fisher, D.R., Schenter, R.E., and Rao, D.V. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat. Res. 1997; 147: 342-348.
61. Charlton, D.E., Utteridge, T.D., and Allen, B.J. Theoretical treatment of human haemopoietic stem cell survival following irradiation by alpha particles. Int. J. Radiat. Biol. 1998; 74: 111-118.
62. Macklis, R.M., Beresford, B.A., Lin, J.Y., Atcher, R.W. and Humm, J.L. Murine hematopoietic ablation by alpha-particle-emitting radiopharmaceuticals: a potential preparative regimen for bone marrow transplantation? Int. J. Oncol. 1993; 2: 711-715.
63. Jurcic, J.G., McDevitt, M.R., Sgouros, G., Ballangrud, Å., Finn, R.D., Ma, D., Geerlings, M.W., Humm, J.L., Brechbiel, M.W., Molinet, R., Apostolidis, C., Larson, S.M., and Scheinberg, D.A. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33). Cancer Biotherapy Radiopharm. 1998; 13: 317.
64. Jurcic, J.G., McDevitt, M.R., Sgouros, G., Ballangrud, Å., Finn, R.D., Geerlings, M.W., Humm, J.L., Molinet, R., Apostolidis, C., Larson, S.M., and Scheinberg, DA. Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33). Blood 1997; 90 (Suppl.): 504a.
65. Sgouros, G., Ballangrud, Å. M, Hamacher, K.A., Jurcic, J.G., Panageas, K.S., McDevitt, M.R., Finn, R.D., Larson, S.M., and Scheinberg, DA. Beta- vs. alphaemitter dose-response analysis in patients. J. Nucl. Med. 2000; 41 (Suppl.): 82P.
66. 213Bi)-labeled anti-PSMA antibody (J591). Cancer Res. 2001; 61: 2008-2014.
67. Behr, T.M., Béhé, M., Jungclas, H., Becker, W., and Sgouros, G. Higher relative biological efficiency (RBE) of alpha-particles: in vitro veritas, in vivo vanitas? Eur. J. Nucl. Med. 2001; 28: 939-940.
68. Behr, T.M., Béhé, M.P. Cholecystokinin-B/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Sem. Nucl. Med. 2002; 32: 97-109.